Seelos Forges Ahead With SLS-002, Says Primary Endpoint Miss Due To Underpowered Trial

 
• By Alaric DeArment
  
Seelos plans to move ahead with SLS-002's development despite a primary endpoint miss in a Phase II study • Source: Shutterstock

More from Clinical Trials

More from R&D